THRYV THERAPEUTICS
Thryv Therapeutics is a genetic disorder that causes a prolongation between the beginning of the QRS complex and the end of the T waveQ and T waves on the EKG, indicating a prolongation of ventricular repolarization and the action potential duration. The lengthening of this complex is associated with unexpected and life-threatening ventricular arrhythmias. Click below to learn more about our programs.
THRYV THERAPEUTICS
Industry:
Biotechnology Precision Medicine Therapeutics
Founded:
2019-01-01
Address:
Laval, Quebec, Canada
Country:
Canada
Website Url:
http://www.thryvtrx.com
Total Employee:
11+
Status:
Active
Contact:
+1 514 973 0915
Email Addresses:
[email protected]
Total Funding:
40.38 M USD
Technology used in webpage:
SPF LetsEncrypt SSL By Default US Privacy User Signal Mechanism Google Apps For Business YouTube GoDaddy DNS DMARC Squarespace Hosted ReCAPTCHA Enterprise
Similar Organizations
Arctic Therapeutics
Arctic Therapeutics (AT) uses bioinformatic approaches and AI to eliminate major risks associated with traditional drug development.
Avstera Therapeutics
Avstera Therapeutics is an oncology-focused biotech company that fulfil unmet needs of cancer patients.
Excision BioTherapeutics
Excision is developing CRISPR-based therapies to cure viral infectious diseases and improve the lives of chronically ill patients.
Scout Bio
Scout Bi is a biotechnology company that provides veterinary, animal health, and gene therapy.
Spark Therapeutics
Spark Therapeutics is focused on the development of gene therapy.
Tmunity Therapeutics
Tmunity Therapeutics is developing novel products to unleash the immunological potential of T cells
VintaBio
VintaBio is a life sciences company that offers cell and gene therapy manufacturing services.
Current Advisors List
Current Employees Featured
Founder
Investors List
Investissement Quebec
Investissement Quebec investment in Convertible Note - Thryv Therapeutics
Lumira Ventures
Lumira Ventures investment in Series A - Thryv Therapeutics
Alexandria Venture Investments
Alexandria Venture Investments investment in Series A - Thryv Therapeutics
Amzak Health Investors
Amzak Health Investors investment in Series A - Thryv Therapeutics
Fonds de solidarité FTQ
Fonds de solidarité FTQ investment in Series A - Thryv Therapeutics
Amplitude Venture Capital
Amplitude Venture Capital investment in Series A - Thryv Therapeutics
Fonds de solidarité FTQ
Fonds de solidarité FTQ investment in Seed Round - Thryv Therapeutics
Official Site Inspections
http://www.thryvtrx.com Semrush global rank: 5.24 M Semrush visits lastest month: 1.48 K
- Host name: 198.185.159.145
- IP address: 198.185.159.145
- Location: New York United States
- Latitude: 40.7157
- Longitude: -74
- Metro Code: 501
- Timezone: America/New_York
- Postal: 10013
More informations about "Thryv Therapeutics"
Thryv Therapeutics
Thryv Therapeutics is pioneering a precision medicine approach to treat Congenital Long QT Syndromes (LQTS), atrial fibrillation, and resistant cancers with potent and selective inhibitors …See details»
Home — Thérapeutiques Thryv
Thryv Therapeutics (previously LQT Therapeutics), has been pioneering a precision medicine approach to treat Long QT Syndrome via SGK1 inhibition since 2019, and our portfolio has evolved to include the treatment of resistant …See details»
Thérapeutiques Thryv
Thérapeutiques Thryv inc. est le les pionnier d'une approche de médecine de précision pour traiter des indications telles que le syndrome du QT long congénital (LQTS), la fibrillation auriculaire et l'insuffisance cardiaque avec …See details»
Board of Directors — Thryv Therapeutics
Mr. Truex is the CEO and Chairman of Thryv Therapeutics (previously LQT Therapeutics). Over the course of two decades he has been involved in over $5 billion of life science financings and strategic transactions.See details»
Our Team - Thryv Therapeutics
Mr. Truex is the CEO and Chairman of Thryv Therapeutics (previously LQT Therapeutics). Over the course of two decades he has been involved in over $5 billion of life science financings and strategic transactions.See details»
Dr. Debra Odink appointed to President and Dr. Shi Yin Foo joins …
Sep 1, 2022 · Thryv Therapeutics Inc. is pleased to announce the appointment of Dr. Debra Odink to President and Chief Development Officer of the company and the addition of Dr. Shi Yin …See details»
Thryv Therapeutics - Crunchbase Company Profile & Funding
Thryv Therapeutics is a precision medicine approach to treat patients with Long QT Syndrome and potentially other arrhythmias. View contacts for Thryv Therapeutics to access new leads …See details»
Thryv Therapeutics Inc. | LinkedIn
Thryv Therapeutics is pioneering a precision medicine approach to treat genetic and drug-induced Long QT Syndromes, atrial fibrillation, and resistant cancers with potent and selective...See details»
Thryv Therapeutics - VentureRadar
Website: https://thryvtrx.com/ Develops a precision medicine approach for treating Long QT Syndrome and resistant/rare cancers through SGK1 inhibition, based in Montreal, Canada. …See details»
Completion of Initial Phase 1 Clinical Study and …
Mar 14, 2023 · Thryv Therapeutics Inc., a clinical stage biotechnology company developing therapies for rare diseases including Congenital Long QT Syndrome (LQTS) and resistant cancers as well as atrial fibrillation announced today the …See details»
Thryv Therapeutics - Overview, News & Similar companies
Dec 11, 2023 · Thryv Therapeutics contact info: Phone number: (514) 973-0915 Website: www.thryvtrx.com What does Thryv Therapeutics do? Thryv Therapeutics is pioneering a …See details»
Our Investors - Thérapeutiques Thryv
Thryv Therapeutics Inc. (previously LQT Therapeutics Inc.), is a privately owned company based in Montreal, Quebec, Canada. They have been pioneering a precision medicine approach to …See details»
Expanding Pipeline Leads to Name Change - Lumira Ventures
Jul 11, 2022 · The new name, Thryv Therapeutics Inc., embodies our commitment to relentlessly pursue therapies which provide lifelong benefits to patients, families, doctors, nurses and …See details»
Thryv — CTI Life Sciences
Thryv Therapeutics (Thryv) is a clinical-stage biotherapeutics company developing a first-in-class treatment for cardiovascular diseases. Thryv’s lead asset, LQT1213, is an SGK1 inhibitor …See details»
Our Investors — Thryv Therapeutics
Amplitude is a full-stack venture capital firm using a unique growth model to build Canadian companies with world-class management teams and scale companies to breakout potential.See details»
Thryv Team - Thérapeutiques Thryv
Meet the team at Thryv Therapeutics. We are a biopharmaceutical company developing kinase inhibitors to treat various conditions, including Long QT Syndrome, arrhythmias and treatment …See details»
Thryv Therapeutics Inc. Announces Participation in the 2024 Bloom ...
Montreal, Quebec-- (Newsfile Corp. - April 4, 2024) - Thryv Therapeutics Inc., a Montreal based biotechnology company pioneering a precision medicine approach to treat indications including...See details»
Press Releases - Thryv Therapeutics
Nov 14, 2024 · Thryv Therapeutics Inc., a biotechnology company pioneering treatments for genetic and cardiometabolic conditions, including congenital Long QT Syndrome, heart failure, …See details»
Pipeline SGK1 — Thérapeutiques Thryv - thryvtrx.ca
At Thryv Therapeutics we're pursuing a number of compounds that inhibit Serum Glucocorticoid Kinase 1 (“SGK1”) for LQTS, life-threatening arrhythmias and treatment-resistant cancers.See details»
Thryv Therapeutics Announces Four Abstracts Accepted for AHA …
Oct 23, 2024 · Thryv Therapeutics is pioneering a precision medicine approach to develop highly selective SGK1 inhibitors to treat Long QT Syndrome, atrial fibrillation and heart failure, with …See details»